Presseportal.ch - Takeda

Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) in Patients Aged 2 years and Older

info@newsaktuell.ch (presseportal.ch) — Fri, 22 Sep 2023 16:16:14 +0200

Takeda [Newsroom]
Zurich (ots/PRNewswire) - - If Approved, Lanadelumab Will be the First Long-Term Prophylactic Treatment of HAE Available in the EU for Patients Under the Age of Six. - Positive Opinion Based on Pivotal Study SHP643-301, Evaluating the Safety Profile ... Lesen Sie hier weiter...

Takeda's ACTOS(R) (pioglitazone) Reduces Risk of Further Heart Attack by 28 Percent in Patients With Type-2 Diabetes

info@newsaktuell.ch (presseportal.ch) — Wed, 16 Nov 2005 17:33:50 +0100

Takeda [Newsroom]
London, November 16 (ots/PRNewswire) - - For Non-US Media Only - PROactive Study Also Shows a 37 Percent Reduction in Acute Coronary Syndrome With ACTOS New results from secondary analyses of the landmark PROactive Study found that ... Lesen Sie hier weiter...

The Lancet Publishes Groundbreaking Proactive Study Showing Type-2 Diabetes Treatment Significantly Reduces Risk of Non-Fatal Heart Attacks, Strokes and Deaths

info@newsaktuell.ch (presseportal.ch) — Fri, 07 Oct 2005 01:03:00 +0200

Takeda [Newsroom]
London (ots/PRNewswire) - - Takeda's ACTOS(R) (pioglitazone HCl) on Top of Standard Treatment Demonstrates Significant Cardiovascular Benefits A study published in The Lancet today shows that Takeda's ACTOS(R) (pioglitazone HCl), an oral ... Lesen Sie hier weiter...

PROactive Study Shows Takeda's ACTOS(R) (pioglitazone HCl) Reduces Heart Attacks, Strokes and Deaths

info@newsaktuell.ch (presseportal.ch) — Mon, 12 Sep 2005 15:16:52 +0200

Takeda [Newsroom]
Athens, Greece (ots/PRNewswire) - Landmark data from the PROactive Study, presented today at the 41st meeting of the European Association for the Study of Diabetes (EASD) demonstrated that ACTOS(R) (pioglitazone HCl) significantly reduces the ... Lesen Sie hier weiter...